AOD-9604: Complete Guide to Fat Loss, Dosage, and Protocols

AOD-9604 is the part of human growth hormone that burns fat, separated from everything else. The full HGH molecule does many things: it raises IGF-1, builds muscle, affects blood glucose, and drives lipolysis. Metabolic Pharmaceuticals spent years isolating exactly which portion of the GH molecule was responsible for the fat-burning effect, removed the rest, and produced AOD-9604.

What you are left with is a peptide that activates lipolysis in fat cells directly, without raising IGF-1, without affecting blood sugar, and without the tissue-growth effects that make full HGH a restricted hormone. It is one of the cleaner fat-loss research compounds from a mechanism standpoint, and its safety profile across the clinical trial program was notably benign.

How AOD-9604 works

Human growth hormone drives fat loss through the beta-3 adrenoceptor pathway in adipocytes. The relevant portion of the GH molecule is the C-terminal fragment, specifically amino acids 176-191. AOD-9604 is a synthetic version of that fragment, with a tyrosine added at the N-terminus to stabilize it.

When AOD-9604 binds to fat cells, it triggers two complementary processes: it activates lipolysis (breaking down stored triglycerides into free fatty acids for fuel) and inhibits lipogenesis (the creation of new fat from carbohydrates). The net effect is that fat cells release their stored fat for oxidation while simultaneously being less able to accumulate new fat from dietary intake.

Critically, AOD-9604 does not interact with the IGF-1 receptor. This is the property that distinguishes it mechanistically from full HGH. No IGF-1 elevation means no anabolic tissue growth, no blood sugar disruption, and no feedback suppression of the hypothalamic-pituitary axis. The compound is targeted specifically at adipose tissue.

What the clinical research shows

AOD-9604 went through a formal pharmaceutical development program at Metabolic Pharmaceuticals (Australia), reaching Phase IIb trials for obesity before the program stalled on statistical significance rather than safety. The data from that program is more rigorous than most research peptides:

• Phase II trials (12-week, obese adults): The 1 mg/day oral dose group showed statistically significant fat loss compared to placebo in some endpoints, but results were inconsistent across dosing groups. The program did not achieve the effect size needed for a Phase III submission.
• Animal data: Consistently robust fat-loss effects in diet-induced obese rodent models, including targeted reduction of visceral fat. Animal data informed the human dose selection.
• Safety: The clinical program found no significant adverse effects on blood glucose, insulin sensitivity, IGF-1 levels, or other metabolic markers across the tested dose range. No serious adverse events were attributed to the compound.
• FDA GRAS status (2014): Metabolic Pharmaceuticals obtained Generally Recognized As Safe classification from FDA for AOD-9604 as a food ingredient. This status reflects a safety determination, not therapeutic efficacy.

The Phase IIb results are the honest constraint to put on AOD-9604 expectations. The compound has a clean mechanism and excellent safety data, but the human fat-loss effect in the clinical trials was modest and variable. Research community experience generally points to subcutaneous dosing producing more consistent results than the oral formulations studied in the trials.

Dosage protocols

Fasted state: Most researchers dose AOD-9604 in a fasted state (at least 2-3 hours after eating, or first thing in the morning). The rationale is that elevated insulin suppresses lipolysis; dosing in a fasted window removes insulin competition and allows the peptide to work on a more receptive metabolic background.

Cycle length: Most research protocols run 4-12 weeks. Unlike GLP-1 compounds, there is no receptor adaptation or tolerance effect documented with AOD-9604, so longer cycles are not structurally problematic. Many researchers cycle it in phases aligned with fat-loss goals rather than treating it as a permanent addition.

AOD-9604 vs other fat loss options

The practical comparison: GLP-1 agonists produce bigger numbers in the clinical data but come with meaningful side effects and, as of mid-2026, significant access restrictions on compounded versions. AOD-9604 has a cleaner tolerability profile and no regulatory complications in research use. Some researchers use both: GLP-1 for appetite and GI effect, AOD-9604 for direct fat cell lipolysis, treating them as complementary rather than competing.

Against other peptides in the weight-loss category: AOD-9604 is more targeted in its mechanism than a full peptide stack built around CJC-1295/Ipamorelin + GH release. GH-axis peptides raise IGF-1 and have broader anabolic effects; AOD-9604 does not. The choice depends on whether you want fat loss only, or fat loss as part of a broader body recomposition.

Side effects and safety profile

AOD-9604 has one of the cleaner safety profiles in the research peptide category, based on the clinical trial program:

• No blood sugar effects: Confirmed across clinical trials. IGF-1 receptor is not activated. Fasting glucose and insulin are unaffected at research doses. This distinguishes it sharply from full HGH.
• No IGF-1 elevation: The IGF-1 receptor binding domain is not present in the 176-191 fragment. Confirmed in clinical data.
• Injection site reactions: Mild redness or temporary soreness at the injection site, consistent with most subQ peptides. Rotating sites and using proper technique minimize this.
• Headache: Occasionally reported, especially early in a cycle. Typically transient.
• Fatigue: A minority of researchers report mild fatigue in the first week. Usually resolves without dose adjustment.
• No HPG axis suppression: Testosterone and LH/FSH are not affected. No PCT required.

The Phase IIb trial program did not identify any dose-limiting toxicities or serious adverse events attributable to AOD-9604. The FDA GRAS classification adds a formal safety review to the record. By research peptide standards, this is a well-characterized safety profile.

What to realistically expect

AOD-9604 is not a dramatic fat-loss compound on its own. The honest framing, based on the clinical data and the research community consensus, is this:

• In a caloric deficit with training, AOD-9604 may meaningfully accelerate fat mobilization and help with stubborn fat areas (visceral and subcutaneous fat respond to beta-3 agonism).
• In a maintenance or mild surplus, the lipolytic effect is partially offset by incoming dietary fat. It will not produce visible fat loss against a bad diet.
• The effect is more visible in leaner individuals (under 20% body fat) where stubborn fat areas are the limiting factor, and less dramatic in higher body fat contexts where caloric deficit is the primary lever.
• Results compound over 8-12 weeks. This is not a fast-acting compound. Set expectations accordingly.

For researchers looking for significant weight loss as a primary goal, the clinical data for GLP-1 compounds is more compelling. AOD-9604 earns its place as a targeted fat-mobilization tool, particularly when stacked with other compounds or used specifically for stubborn fat in the later stages of body recomposition.

Sourcing considerations

AOD-9604 is a well-defined peptide with a known sequence, which makes third-party verification straightforward. Key checks:

• HPLC and mass spectrometry COA confirming the 176-191 fragment sequence
• Purity of 98%+ on the COA
• Sterile preparation for injection use
• Cold-chain shipping (peptides in solution degrade faster; lyophilized powder is more stable)
• Lot number traceability to the COA

The peptide bureau vendor scorecard evaluates vendors on COA verification, third-party testing, and shipping practices. AOD-9604 is carried by several vendors in the scorecard.